![]() The initial version of the Colorado bill would have affirmed the right of medical marijuana patients to use cannabis products at work and would have prevented employers from firing or refusing to hire workers who use marijuana off the job. And, in light of opposition, a Colorado bill will be softened to studying the issue. A California bill has been assigned to a committee, but hasn’t yet moved further. ![]() A bill filed in Washington state this session already has been tabled. The laws generally make exceptions for certain employers and occupations.īut bills have stumbled elsewhere because of opposition from business groups and disagreements over how to measure marijuana intoxication. And Nevada bans employers from refusing to hire someone solely because they fail a marijuana test. New Jersey and New York ban employers from discriminating against workers who legally use marijuana medically or recreationally. So far, 14 states and Washington, D.C., have banned employers from discriminating against workers who use marijuana for medical reasons. And they say workplace drug testing is an equity issue, as tests are more common in blue-collar jobs and disproportionately affect non-White workers.īut certain employers are required to test for marijuana under federal law-the federal government classifies marijuana as a dangerous drug akin to heroin-and others want to make sure they don’t employ drug users who could threaten workplace safety. They note that workplace drug tests don’t measure whether someone is high at the time of the test, just whether they’ve used recently. ![]() But in most of those states, people can be fired or denied a job for using cannabis in their free time.Ĭannabis legalization advocates want states to do more to protect workers. Thirty-seven states now allow adults to use marijuana medically, recreationally or both. doi: 10.1001/ story was updated March 2, 2022, to clarify the prospects of a bill in California. ![]() Urinary tetrahydrocannabinol after 4 weeks of a full-spectrum, high-cannabidiol treatment in an open-label clinical trial. Current results indicate this may not be true,” and the results may have “potential for adverse consequences, including loss of employment and legal or treatment ramifications, despite the legality of hemp-derived products.”ĭahlgren MK, Sagar KA, Lambros AM, et al. “It is often assumed individuals using hemp-derived products will test negative for THC. “Despite limitations in sample size and diversity, these findings have important public health implications,” the authors concluded. Seven patients tested positive for THC, and 7 tested negative (1 patient dropped out). Presence of THC was assessed using a presumptive test panel, followed by gas chromatograph-mass spectrometry performed by Quest Diagnostics. ![]() To determine whether use of such a product might cause a positive urine drug test for THC, the authors enrolled 15 individuals being treated for anxiety to receive a full-spectrum, high-CBD extract containing 9.97 mg/mL of CBD (1.04%) and 0.23 mg/mL of Δ9-THC (0.02%), 1 mL sublingually 3 times per day for 4 weeks. Use of so-called “full-spectrum” formulations of cannabidiol (CBD) products can cause users to test positive for THC, the component of marijuana that causes euphoria, according to an open-label study published in JAMA Psychiatry.įull-spectrum CBD products contain THC, but at levels too low (≤0.30% by weight) to meet federal guidelines for Schedule 1 classification. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |